v3.26.1
Segment Reporting - Schedule of Segment Reported Segment Revenues, and Significant (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Segment Reporting Information [Line Items]            
Revenues $ 14,285   $ 11,786   $ 28,029 $ 23,090
Operating costs and expenses:            
Cost of product revenue [1] 1,273   685   2,305 1,519
Pemivibart [2] 265   906   453 2,297
VYD2311 [3] 20,350   1,011   43,153 2,513
VBY329 [4] 80   41   244 83
VMS063 [5] 182   50   311 50
Early-stage programs 175   75   204 160
Total direct, external research and development expenses by program 21,052   2,083   44,365 5,103
Stock-based compensation expense 2,895   3,180   5,592 6,006
Total research and development expense [6] 29,367   9,573   60,098 20,214
Total selling, general and administrative expense 29,465   16,588   54,582 33,339
Total operating costs and expenses 60,105   26,846   116,985 55,072
Loss from operations (45,820)   (15,060)   (88,956) (31,982)
Other income:            
Other income, net [7] 1,427   400   3,163 1,033
Total other income, net 1,427   400   3,163 1,033
Net Income (Loss) (44,393) $ (41,400) (14,660) $ (16,289) (85,793) (30,949)
Selling, General and Administrative Expenses [Member]            
Operating costs and expenses:            
Personnel expense 9,847   5,230   17,535 10,720
Stock-based compensation expense 2,154   2,393   4,118 4,388
Sales and marketing costs 6,961   3,341   12,179 6,301
Other selling, general and administrative expense 10,503   5,624   20,750 11,930
Total selling, general and administrative expense 29,465   16,588   54,582 33,339
Research and Development            
Operating costs and expenses:            
Personnel expense 3,532   2,743   6,699 5,923
Stock-based compensation expense 741   787   1,474 1,618
Other research and development expense 4,042   3,960   7,560 7,570
Total research and development expense 29,367   9,573   60,098 20,214
Product [Member]            
Segment Reporting Information [Line Items]            
Revenues $ 14,285   $ 11,786   $ 28,029 $ 23,090
[1] Includes related-party amounts of $571 and $1,121 for the three and six months ended June 30, 2026, respectively, and $472 and $924 for the three and six months ended June 30, 2025, respectively (see Note 15).
[2] In March 2023, the Company announced the nomination of VYD222 (pemivibart) as a novel mAb therapeutic option for COVID-19.
[3] In March 2024, the Company announced the nomination of VYD2311 as a novel mAb therapeutic option for COVID-19.
[4] In November 2025, the Company announced the nomination of VBY329 as an RSV mAb candidate for preclinical development.
[5] In April 2026, the Company announced the nomination of VMS063 as a measles mAb candidate for preclinical development.
[6] Includes related-party amounts of $1,129 and $2,255 for the three and six months ended June 30, 2026, respectively, and $1,140 and $2,268 for the three and six months ended June 30, 2025, respectively (see Note 15).
[7] Includes interest income of $1,503 and $405 for the three months ended June 30, 2026 and 2025, respectively, and interest income of $3,246 and $1,033 for the six months ended June 30, 2026 and 2025, respectively.